Efficacy and Safety of NNC0487-0111 s.c. Once Weekly in Participants With Obesity Who Have Reached Target Dose During run-in Period (AMAZE 12)
Novo Nordisk A/S
Summary
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Male or female (sex at birth). * Age 18 years or above at the time of signing the informed consent. Exclusion Criteria: * Glycated haemoglobin (HbA1c) greater than or equal to ≥ 6.5% \[48 millimoles per mole (mmol/mol)\] as measured by the central laboratory at screening. * History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records. * Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP 1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment), or amylin analogues before s…
Interventions
- DrugNNC0487-0111
NNC0487-0111 will be administered subcutaneously.
- DrugPlacebo (matched to NNC0487-0111)
Placebo will be administered subcutaneously.
Locations (72)
- Pinnacle Research Group LLCAnniston, Alabama
- Diablo Clinical Research, Inc.Walnut Creek, California
- Florida Inst For Clin Res LLCOrlando, Florida
- Endeavor HealthSkokie, Illinois
- Midwest Inst For Clin ResIndianapolis, Indiana
- Medication Mgmnt, LLC_GrnsboroGreensboro, North Carolina